<p>紐約，2025 年 12 月 4 日（GLOBE NEWSWIRE）——Protara Therapeutics, Inc.（納斯達克：TARA）（“Protara”）是一家開發用於治療癌症和罕見疾病的變革性療法的臨牀階段公司，今天宣佈其承銷的公開發行定價為 13,043,479 股普通股，公眾發行價格為每股 5.75 美元。此外，Protara 已向承銷商授予 30 天的選擇權，以以公眾發行價格購買最多 1,956,521 股普通股，扣除承銷折扣和佣金。此次發行的所有股份均由 Protara 出售。預計此次發行的總收益約為 7500 萬美元，未扣除承銷折扣和佣金及 Protara 應支付的發行費用，並且不包括承銷商行使購買額外股份的選擇權。此次發行預計將於 2025 年 12 月 8 日完成，前提是滿足慣常的交割條件。Protara 打算將此次發行所獲得的淨收益用於資助 TARA-002 的臨牀開發，以及其他臨牀項目的開發。Protara 還可能將此次發行的淨收益用於營運資金和其他一般企業用途。</p>
<p>摩根大通、TD Cowen 和 Piper Sandler 擔任聯合賬簿管理人。LifeSci Capital 擔任此次發行的主承銷商。H.C. Wainwright &amp; Co.擔任此次發行的管理人。</p>
<p>普通股將根據美國證券交易委員會（“SEC”）於 2023 年 11 月 14 日宣佈生效的有效貨架註冊聲明（表格 S-3，文件編號 333-275290）發行。此次發行僅通過招股説明書補充及隨附的招股説明書進行。與此次發行相關的最終招股説明書補充將在 SEC 備案，並將在 SEC 的網站 www.sec.gov 上提供。最終招股説明書補充及隨附的招股説明書在可用時可從摩根大通證券有限責任公司（J.P. Morgan Securities LLC）辦公室獲取，地址為紐約公園大道 270 號，郵政信箱，紐約，郵政編碼 10017，或通過電子郵件聯繫 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；TD Securities（USA）有限責任公司，地址為紐約長島大道 1155 號，郵政編碼 11717，或通過電子郵件聯繫 TDManualrequest@broadridge.com；或 Piper Sandler &amp; Co.，地址為明尼阿波利斯北 5 街 350 號，1000 套房，郵政編碼 55401，注意：招股説明書部門，電話（800）747-3924，或通過電子郵件聯繫 prospectus@psc.com。</p>
<p>本新聞稿不構成出售任何這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的銷售，若在該州或司法管轄區內的要約、邀請或銷售在註冊或符合適用證券法之前是非法的。</p>
<p><strong>前瞻性聲明</strong></p>
<p>本新聞稿中關於非歷史事實事項的聲明屬於 1995 年《私人證券訴訟改革法》所定義的 “前瞻性聲明”。Protara 在某些情況下可能會使用 “預測”、“相信”、“潛在”、“提議”、“繼續”、“設計”、“估計”、“預期”、“期望”、“計劃”、“打算”、“可能”、“可以”、“會”、“應該” 或其他引用未來事件、條件或情況的不確定性以識別這些前瞻性聲明的詞語或表達。這些前瞻性聲明包括但不限於關於公開發行的時間、規模和完成情況以及相關收益的預期使用的聲明，並不保證未來的表現或結果，並涉及重大風險和不確定性。實際結果、發展和事件可能與這些前瞻性聲明所表達或暗示的內容有重大不同。導致前瞻性聲明不確定性的因素包括：Protara 完成此次發行的能力是否符合提議的條款，或根本無法完成，以及 Protara 對發行收益使用的預期。與前瞻性聲明相關的其他重要因素，包括額外的風險和不確定性，已在 Protara 向 SEC 提交的文件和報告中的 “風險因素” 標題下及其他地方進行了更全面的描述。本新聞稿中包含的所有前瞻性聲明僅在作出之日有效，並基於管理層在該日期的假設和估計。Protara 沒有義務更新任何前瞻性聲明，無論是由於收到新信息、未來事件的發生還是其他原因，除非法律要求。</p>
<p><strong>公司聯繫方式：</strong></p>
<p>賈斯廷·奧馬利（Justine O'Malley）</p>
<p>Protara Therapeutics</p>
<p>Justine.OMalley@protaratx.com</p>
<p>646-817-2836</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UTVOQ00zTXpBM09UZzVJekl4T0RrM05qZz0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UTVOQ00zTXpBM09UZzVJekl4T0RrM05qZz0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png"/></p>

TARA

<p>Protara Therapeutics 宣佈以每股 5.75 美元公開發行 13,043,479 股，融資總額為 7500 萬美元。此次發行包括承銷商在 30 天內購買額外 1,956,521 股的選擇權。募集資金將用於 TARA-002 及其他項目的臨牀開發，摩根大通、TD Cowen 和 Piper Sandler 擔任聯合管理人。此次發行將於 2025 年 12 月 8 日結束</p>

<p>NEW YORK, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the pricing of its underwritten public offering of 13,043,479 shares of its common stock at a price to the public of $5.75 per share. In addition, Protara has granted the underwriters a 30-day option to purchase up to an additional 1,956,521 shares of common stock at the public offering price, less underwriting discounts and commissions. All shares in the offering are being sold by Protara. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and offering expenses payable by Protara and excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on December 8, 2025, subject to satisfaction of customary closing conditions. Protara intends to use the net proceeds received from the offering to fund the clinical development of TARA-002, as well as the development of other clinical programs. Protara may also use the net proceeds from the offering for working capital and other general corporate purposes.</p>
<div class="lb-trans"><p>紐約，2025 年 12 月 4 日（GLOBE NEWSWIRE）——Protara Therapeutics, Inc.（納斯達克：TARA）（“Protara”）是一家開發用於治療癌症和罕見疾病的變革性療法的臨牀階段公司，今天宣佈其承銷的公開發行定價為 13,043,479 股普通股，公眾發行價格為每股 5.75 美元。此外，Protara 已向承銷商授予 30 天的選擇權，以以公眾發行價格購買最多 1,956,521 股普通股，扣除承銷折扣和佣金。此次發行的所有股份均由 Protara 出售。預計此次發行的總收益約為 7500 萬美元，未扣除承銷折扣和佣金及 Protara 應支付的發行費用，並且不包括承銷商行使購買額外股份的選擇權。此次發行預計將於 2025 年 12 月 8 日完成，前提是滿足慣常的交割條件。Protara 打算將此次發行所獲得的淨收益用於資助 TARA-002 的臨牀開發，以及其他臨牀項目的開發。Protara 還可能將此次發行的淨收益用於營運資金和其他一般企業用途。</p>
</div><p>J.P. Morgan, TD Cowen and Piper Sandler are acting as joint book-running managers. LifeSci Capital is acting as a lead manager of the offering. H.C. Wainwright &amp; Co. is acting as a manager of the offering.</p>
<div class="lb-trans"><p>摩根大通、TD Cowen 和 Piper Sandler 擔任聯合賬簿管理人。LifeSci Capital 擔任此次發行的主承銷商。H.C. Wainwright &amp; Co.擔任此次發行的管理人。</p>
</div><p>The shares of common stock will be issued pursuant to an effective shelf registration statement on Form S-3 (File No. 333-275290) that was declared effective on November 14, 2023 by the U.S. Securities and Exchange Commission (the “SEC”). The offering is being made only by means of a prospectus supplement and the accompanying prospectus. A final prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC’s website, at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering, when available, may be obtained from the offices of J.P. Morgan Securities LLC, 270 Park Avenue, New York, New York 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717 or by email at TDManualrequest@broadridge.com; or Piper Sandler &amp; Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com.</p>
<div class="lb-trans"><p>普通股將根據美國證券交易委員會（“SEC”）於 2023 年 11 月 14 日宣佈生效的有效貨架註冊聲明（表格 S-3，文件編號 333-275290）發行。此次發行僅通過招股説明書補充及隨附的招股説明書進行。與此次發行相關的最終招股説明書補充將在 SEC 備案，並將在 SEC 的網站 www.sec.gov 上提供。最終招股説明書補充及隨附的招股説明書在可用時可從摩根大通證券有限責任公司（J.P. Morgan Securities LLC）辦公室獲取，地址為紐約公園大道 270 號，郵政信箱，紐約，郵政編碼 10017，或通過電子郵件聯繫 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；TD Securities（USA）有限責任公司，地址為紐約長島大道 1155 號，郵政編碼 11717，或通過電子郵件聯繫 TDManualrequest@broadridge.com；或 Piper Sandler &amp; Co.，地址為明尼阿波利斯北 5 街 350 號，1000 套房，郵政編碼 55401，注意：招股説明書部門，電話（800）747-3924，或通過電子郵件聯繫 prospectus@psc.com。</p>
</div><p>This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the applicable securities laws of such state or jurisdiction.</p>
<div class="lb-trans"><p>本新聞稿不構成出售任何這些證券的要約或購買這些證券的要約邀請，也不應在任何州或司法管轄區內進行這些證券的銷售，若在該州或司法管轄區內的要約、邀請或銷售在註冊或符合適用證券法之前是非法的。</p>
</div><p><strong>Forward-looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性聲明</strong></p>
</div><p>Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding the timing, size and completion of the public offering as well as the expected use of proceeds related thereto are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: Protara’s ability to complete the offering on the proposed terms, or at all, and Protara’s expectations related to the use of proceeds from the offering. Additional important factors to be considered in connection with forward-looking statements, including additional risks and uncertainties, are described more fully under the caption “Risk Factors” and elsewhere in Protara’s filings and reports with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.</p>
<div class="lb-trans"><p>本新聞稿中關於非歷史事實事項的聲明屬於 1995 年《私人證券訴訟改革法》所定義的 “前瞻性聲明”。Protara 在某些情況下可能會使用 “預測”、“相信”、“潛在”、“提議”、“繼續”、“設計”、“估計”、“預期”、“期望”、“計劃”、“打算”、“可能”、“可以”、“會”、“應該” 或其他引用未來事件、條件或情況的不確定性以識別這些前瞻性聲明的詞語或表達。這些前瞻性聲明包括但不限於關於公開發行的時間、規模和完成情況以及相關收益的預期使用的聲明，並不保證未來的表現或結果，並涉及重大風險和不確定性。實際結果、發展和事件可能與這些前瞻性聲明所表達或暗示的內容有重大不同。導致前瞻性聲明不確定性的因素包括：Protara 完成此次發行的能力是否符合提議的條款，或根本無法完成，以及 Protara 對發行收益使用的預期。與前瞻性聲明相關的其他重要因素，包括額外的風險和不確定性，已在 Protara 向 SEC 提交的文件和報告中的 “風險因素” 標題下及其他地方進行了更全面的描述。本新聞稿中包含的所有前瞻性聲明僅在作出之日有效，並基於管理層在該日期的假設和估計。Protara 沒有義務更新任何前瞻性聲明，無論是由於收到新信息、未來事件的發生還是其他原因，除非法律要求。</p>
</div><p><strong>Company Contact:</strong></p>
<div class="lb-trans"><p><strong>公司聯繫方式：</strong></p>
</div><p>Justine O'Malley</p>
<div class="lb-trans"><p>賈斯廷·奧馬利（Justine O'Malley）</p>
</div><p>Protara Therapeutics</p>
<div class="lb-trans"><p>Protara Therapeutics</p>
</div><p>Justine.OMalley@protaratx.com</p>
<div class="lb-trans"><p>Justine.OMalley@protaratx.com</p>
</div><p>646-817-2836</p>
<div class="lb-trans"><p>646-817-2836</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UTVOQ00zTXpBM09UZzVJekl4T0RrM05qZz0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NzQ5NCM3MzA3OTg5IzIxODk3Njg="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png" alt="" original-src="https://ml.globenewswire.com/media/ODU3MTI1ZjEtMzkxZS00NDhiLTgxOWUtYWQ2ZjI4NDY3NTg3LTEyMDEzMjEtMjAyNS0xMi0wNS1lbg==/tiny/Protara-Therapeutics.png"/></p>

Protara 宣佈 7500 萬美元公開發行的定價 | TARA 股票新聞